Search clinical trials for: Compensated Liver Cirrhosis

Total 18260 results

89bio, Inc.

Not yet recruiting

Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Not yet recruiting

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis (SAVE-D)

Hepatitis D

Italy
King Chulalongkorn Memorial Hospital
Chulalongkorn University

Not yet recruiting

The Efficacy of Aerobic Exercise Training on Autonomic Nervous System and Endothelial Function in Patients With Compensated Cirrhosis

Physical Activity | Cirrhosis | Sarcopenia | Heart Rate Variability | Physical Functional Performance | Lifestyle Modification | Autonomic Dysfunction | Endothelial Function | Autonomic Nervous System | Aerobic Exercises | Flow Mediated Dilation

Thailand
Institute of Liver and Biliary Sciences, India

Not yet recruiting

To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis

Decompensated Cirrhosis | Compensated Cirrhosis

India
CymaBay Therapeutics, Inc.

Recruiting

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis (AFFIRM)

Primary Biliary Cholangitis

United States, Korea, Republic of, Turkey
Xijing Hospital of Digestive Diseases

Recruiting

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis

China
Huashan Hospital
Liuzhou Workers Hospital; The First Affiliated Hospital of Anhui Medical University and other collaborators

Not yet recruiting

Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients (CHESS2204)

Cirrhosis | Varices | Non-invasive Evaluation
Madrigal Pharmaceuticals, Inc.

Recruiting

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Cirrhosis, Liver | NASH

United States, Puerto Rico
Vir Biotechnology, Inc.

Recruiting

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Cirrhosis | Hepatic Impairment

United States
Peking University People's Hospital

Not yet recruiting

Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis

Hepatitis C | Cirrhosis
University of Southern California

Not yet recruiting

The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis

Cirrhosis | Portal Hypertension | Compensated Cirrhosis
Hepatopancreatobiliary Surgery Institute of Gansu...
LanZhou University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University... and other collaborators

Recruiting

A Combined Model Based on Spleen Stiffness, Liver Stiffness and Platelets for Assessing Portal Hypertension in Compensated Cirrhosis (CHESS2202)

Portal Hypertension

China
Peking University First Hospital

Recruiting

The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China (BDTAF)

Chronic Hepatitis B | Chronic Hepatitis C

China
Hepatopancreatobiliary Surgery Institute of Gansu...
Zagazig University; LanZhou University; Korea University; Ruijin Hospital; Hyogo... and other collaborators

Not yet recruiting

CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102)

Compensated Advanced Chronic Liver Disease

China, Korea, Republic of, Japan, Egypt, India
CymaBay Therapeutics, Inc.

Recruiting

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Hepatic Impairment | Compensated Cirrhosis | Primary Biliary Cholangitis

Korea, Republic of, United States, Spain, United Kingdom
Assiut University

Not yet recruiting

Prophylactic Antibiotics in Prevention of Spontaneous Bacterial Peritonitis in Compensated Liver Cirrhosis

Liver Cirrhosis | Upper Gastrointestinal Bleeding
Indiana University

Recruiting

Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

NASH - Nonalcoholic Steatohepatitis | Cirrhosis, Liver

United States
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis

Hepatitis B | Compensated Cirrhosis

China
Nanfang Hospital of Southern Medical University
LanZhou University; Zhongda Hospital; Ankara University; Xingtai People's Hospital and other collaborators

Recruiting

Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)

Compensated Cirrhosis

China, Turkey, Thailand
Nanfang Hospital of Southern Medical University
LanZhou University; Chulalongkorn University; Beijing 302 Hospital; Xijing Hospital... and other collaborators

Recruiting

Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Compensated Cirrhosis (Pan-CHESS1801)

Compensated Liver Cirrhosis | Gastroesophageal Varices Bleeding

China, Japan, Indonesia, Thailand, Turkey
Institute of Liver and Biliary Sciences, India

Recruiting

The Natural History and Prognostic Factors of Compensated Cirrhosis.

Compensated Cirrhosis

India
Jorge L Poo

Completed

Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis. (ODISEA)

Cirrhosis, Liver | Liver Fibrosis | Chronic Liver Disease
Bristol-Myers Squibb

Terminated

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Germany, Taiwan, United Kingdom, Spain, Argentina, Brazil, France, Israel, Italy, Japan, Korea, Republic of, Belgium, Canada, Puerto Rico, Switzerland
VA Office of Research and Development

Active, not recruiting

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis (SACRED)

Cirrhosis

United States
United Arab Emirates University
Tawam Hospital

Completed

Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis

Compensated Cirrhosis | Non-alcoholic Fatty Liver | Esophageal Varices

United Arab Emirates
Intercept Pharmaceuticals

Completed

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Spain, France, Australia, New Zealand, Puerto Rico, Germany, Canada, United Kingdom, Hungary, Poland, Ukraine
Gilead Sciences

Terminated

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

Primary Sclerosing Cholangitis | Compensated Cirrhosis

United States
Centre Hospitalier Universitaire, Amiens

Withdrawn

Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence. (NalmeCir)

Alcohol Dependence | Cirrhosis | Nalmefene

France
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)

Nonalcoholic Steatohepatitis | Compensated Cirrhosis

United States, Australia, Belgium, France, Germany, Hong Kong, Poland, Puerto Rico, United Kingdom
Institute of Liver and Biliary Sciences, India

Completed

Liver and Splenic Stiffness in Predicting Esophageal Varices Needing Treatment in NASH Related Compensated Advanced Chronic Liver Disease.

Chronic Liver Disease

India
AbbVie

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection (DORA)

Hepatitis C Virus (HCV)

United States, Belgium, Canada, Germany, Japan, Puerto Rico, Russian Federation, Spain, United Kingdom
Akero Therapeutics, Inc

Active, not recruiting

A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)

NASH - Nonalcoholic Steatohepatitis

United States, Mexico, Puerto Rico
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

Algeria, Australia, Belgium, Bulgaria, Canada, Denmark, Finland, France, Germany, Greece, Israel, Italy, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Saudi Arabia, Spain, Switzerland, Turkey, Austria, Ireland and more
University of Kansas Medical Center

Completed

OPTIMIzing muScle Preservation in paTients wIth Cirrhosis (OPTIMISTIC)

Obesity | Sarcopenia | Compensated Cirrhosis

United States
Meridian Bioscience, Inc.

Completed

Assessing Portal Hypertension With Methacetin Breath Test

Patients With Compensated Liver Cirrhosis

United States, France, Switzerland, Spain
AbbVie

Completed

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II)

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

United States
Pinnacle Clinical Research, PLLC

Completed

An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis

Fatty Liver | Fibrosis, Liver | Compensated Cirrhosis | Non-alcoholic Steatohepatitis

United States
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Gilead Sciences

Completed

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis

Hepatitis C Virus Infection

Japan
GlaxoSmithKline

Completed

Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis

Hepatitis B, Chronic

China
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)

Hepatitis C, Chronic
AbbVie

Completed

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

HCV | Hepatitis C Infection | Genotype 4
AbbVie

Completed

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection (ENDURANCE-5 6)

Hepatitis C Virus (HCV)

United States, Australia, Belgium, Canada, France, New Zealand, Singapore, South Africa, Vietnam
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)

Hepatitis C Virus | Chronic Hepatitis C Virus
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) (EXPEDITION-2)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
AbbVie

Completed

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection

Chronic Hepatitis C | Hepatitis C Virus | HCV
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)

Hepatitis C Virus Infection | Chronic Hepatitis C | Compensated Cirrhosis
AbbVie

Completed

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)

Hepatitis C Virus Infection | Chronic Hepatitis C | Human Immunodeficiency Virus Infection | Compensated Cirrhosis and Non-cirrhotics
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie

Completed

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)

Compensated Cirrhosis | Chronic Hepatitis C Infection

3

Subscribe